Outcomes of patients with diffuse systemic sclerosis eligible for autologous stem cell transplantation managed with conventional therapy.
Kate GregoryDylan HansenRoss PenglaseDiane ApostolopoulosGene-Siew NgianWendy StevensKathleen MorrisroeNava FerdowsiLaura J RossJennifer WalkerHelen CooleyPeter YoussefKathleen TymmsLauren HostSusanna M ProudmanJohn MooreMandana NikpourJoanne SahharPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
ASCS patients meeting ASTIS and/or SCOT inclusion criteria who were managed without ASCT have similar event-free survival (EFS) at four years than patients receiving ASCT, and better EFS than those receiving cyclophosphamide in the ASTIS and SCOT trials. This may reflect confounders unable to be controlled for, including survivor bias, but may also reflect improved standard of care for dcSSc over time.
Keyphrases
- systemic sclerosis
- stem cell transplantation
- high dose
- free survival
- interstitial lung disease
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- chronic kidney disease
- palliative care
- bone marrow
- prognostic factors
- type diabetes
- low grade
- metabolic syndrome
- quality improvement
- stem cells
- patient reported outcomes
- skeletal muscle
- affordable care act